Evercore ISI Downgrades Chinook Therapeutics (KDNY) to In Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts KDNY Hot Sheet
Price: $40.39 --0%
Rating Summary:
2 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
2 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
Evercore ISI analyst Josh Schimmer downgraded Chinook Therapeutics (NASDAQ: KDNY) from Outperform to In Line with a price target of $40.00 (from $30.00).
For an analyst ratings summary and ratings history on Chinook Therapeutics click here. For more ratings news on Chinook Therapeutics click here.
Shares of Chinook Therapeutics closed at $37.87 yesterday.
You May Also Be Interested In
- BofA Securities Downgrades Central Bancompany (CBC) to Neutral
- Mosaic (MOS) PT Lowered to $20 at Mizuho
- Truist Securities Downgrades Gartner (IT) to Hold
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
